Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil-Shandong Cancer Hospital and Institute-breast cancer
- Development stage
- Unknown
- Lead developer
- Shandong Cancer Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This entry refers to a collection of neoadjuvant chemotherapy (NAC) regimens—specifically TAC (docetaxel, doxorubicin, cyclophosphamide), TC (docetaxel, cyclophosphamide), TA (docetaxel, doxorubicin), CAF (cyclophosphamide, doxorubicin, 5-fluorouracil), and CEF (cyclophosphamide, epirubicin, 5-fluorouracil)—evaluated in the Phase 3 BCSMANC clinical trial conducted by Shandong Cancer Hospital and Institute. These regimens are employed to treat breast cancer by inducing tumor shrinkage prior to surgery. The components include taxanes (docetaxel) that stabilize microtubules, anthracyclines (doxorubicin, epirubicin) that inhibit topoisomerase II and intercalate DNA, alkylating agents (cyclophosphamide) that cross-link DNA, and antimetabolites (5-fluorouracil) that inhibit thymidylate synthase. The trial specifically investigates the shrinkage patterns of tumors using 3D pathological and MRI reconstruction to optimize breast-conserving surgery outcomes.
- Other names
- TACTCTACAFCEFNeoadjuvant Chemotherapy Regimens (BCSMANC Trial)
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil-Shandong Cancer Hospital and Institute-breast cancer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC + TC + TA + cyclophosphamide + doxorubicin + fluorouracil + cyclophosphamide + epirubicin + fluorouracil-Shandong Cancer Hospital and Institute-breast cancer.